
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways PLC is advancing its proprietary psilocybin therapy, COMP360, targeting treatment-resistant depression (TRD) with promising efficacy data indicating potential superiority over existing treatments like Spravato, which recently surpassed $1 billion in annual revenue. The company's innovative therapeutic approach, designed to address a large and underserved patient population, suggests significant commercial viability, particularly with projections for expanding into post-traumatic stress disorder (PTSD) as mental health initiatives for veterans gain government support. The favorable data regarding the durability of response from COMP360, with patients showing sustained benefits for up to 12 weeks, further reinforces the potential for a successful treatment model, positioning Compass Pathways for positive growth in the mental health market.
Bears say
Compass Pathways PLC faces significant risks regarding the FDA approval of its psilocybin therapy, COMP360, following a general trend of negative sentiment in the psychedelic sector, highlighted by Lykos Therapeutics' unfavorable AdComm and subsequent Complete Response Letter (CRL). The overarching concerns stem from the potential for COMP360 and similar pipeline programs to encounter clinical trial failures or safety issues, which could severely hamper the company's prospects. Additionally, a sustained response rate of only ~20% in related studies raises questions about the efficacy of its treatment approach, further contributing to a cautious outlook on the company's stock performance.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares